☀ Morning Good News for Today
On October 8, the FDA approved an additional after-surgery treatment option for people with a specific biomarker-defined form of Stage III colon cancer. [1] [2] [3] The decision covers intravenous atezolizumab with fluoropyrimidine-and-oxaliplatin chemotherapy for adults and children age two and older whose completely resected Stage III colon cancer is mismatch repair deficient, or dMMR. [1]
Good news in 30 seconds
- The approval applies to Stage III dMMR colon cancer after complete surgery—not to every colon cancer. [1] [3]
- In the randomized ATOMIC trial, 711 adults and one pediatric patient were enrolled; the disease-free-survival hazard ratio was 0.50, and median disease-free survival was not reached in either group. [1] [2]
- The FDA also approved a subcutaneous atezolizumab-hyaluronidase formulation for adults and children age 12 and older who weigh at least 40 kilograms, with the same chemotherapy backbone. [1] [3]
What happened
The FDA completed a regulatory decision for atezolizumab plus chemotherapy as adjuvant treatment—treatment given after surgery—for this narrowly defined patient group. The intravenous regimen was approved for patients age two and older. A second formulation delivered under the skin was approved for patients age 12 and older who weigh at least 40 kilograms. [1] [2] [3]
Mismatch-repair status is not just alphabet soup in this setting; it helps define who the new indication is for. The practical question is whether a completely resected Stage III tumor is dMMR and whether the oncology team judges the option appropriate for the individual patient. [1] [3]
The decision rests on a randomized trial rather than a future promise. FDA reported a disease-free-survival hazard ratio of 0.50 for the atezolizumab combination versus mFOLFOX6 alone, with a 95% confidence interval of 0.35 to 0.73. [1] This result describes the relative hazard on that trial endpoint; it does not mean every patient has a 50% chance of benefit.
Why this made us smile
Cancer care comes with enough acronyms to make a bowl of alphabet soup look underqualified. Here, one of them matters: dMMR helps identify the specific group covered by the approval.
What it could mean for everyday people
If this diagnosis applies to you or someone you care for, a useful conversation with the oncology team is how the tumor’s mismatch-repair status was established, whether the new indication fits, which route is medically appropriate, and how the benefits and risks compare with the existing plan. This article is for an informed clinician discussion, not self-treatment or a promise of outcome. [1] [3]
Keep the confetti factual
AJMC reported that overall survival did not differ significantly at the analyzed follow-up. It also reported grade 3 or higher adverse events in 84.1% of patients receiving the combination and 71.9% receiving mFOLFOX6 alone, with two treatment-related deaths in the combination arm. [2] The FDA lists serious immune-mediated and other warnings. [1] Longer-term survival benefit, individual eligibility, insurance coverage, and real-world uptake remain unknown. Reviews by regulators in Australia, Canada, Israel, and Switzerland were still ongoing at this reporting cutoff. [1]
One happy thing to carry with you
A completed approval has turned one carefully measured trial result into another option that oncology teams can evaluate with eligible patients. That is real progress—specific, bounded, and worth welcoming without pretending the hard parts disappeared. [1] [2] [3]
Sources and reporting notes
- U.S. Food and Drug Administration — “FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer” (October 8, 2026)
- AJMC — “FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer” (October 8, 2026; updated October 8)
- CURE — “FDA Approves Tecentriq Plus Chemotherapy for Stage 3 dMMR Colon Cancer” (October 8, 2026)
How we know: The FDA establishes the approval, indication, trial endpoint and official warnings. AJMC independently matches the decision and adds peer-reviewed overall-survival and adverse-event context. CURE independently matches the patient group, after-surgery setting, trial design and route limits. Both news reports ultimately rely on the FDA for the regulatory event; they are corroboration, not second regulators.